Brinzolamide Drug Asset Due Diligence Report 2026

This Brinzolamide Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Brinzolamide can convert its Small molecule drug profile and CAs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Brinzolamide (query alias: brinzolamide)
Modality / target	Small molecule drug; CAs; CAs inhibitors
Highest global status	Approved
Originator	Alcon AG
Active developers	Novartis Europharm Ltd., Sandoz, Inc., Alcon AG

The MCP disease footprint includes Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
CTRI/2024/07/071413	Not Applicable	Open to Recruitment	660	Not disclosed
CTRI/2023/06/054478	Not Applicable	Completed	208	Not disclosed
JPRN-jRCTs051250145	Not Applicable	Recruiting	80	Change in intraocular pressure (at 2 hours after the eye drop) from visit 1 (baseline) to visit 2 (week 4)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Therapeutic Equivalence Study of Generic Brinzolamide 1% Ophthalmic Suspension Compared to Reference Listed Drug Azopt® (Brinzolamide) Ophthalmic Suspension 1% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension.

Phase 3; n=599; evaluation: not stated. Reported fields: Baseline- Left Eye 08:00(Mean) = 24.92 mmHg (Standard Deviation, 2.290); Baseline- Left Eye 08:00(Mean) = 25.06 mmHg (Standard Deviation, 2.363); -

Multi-Center, Randomized, Double-Masked, Active Controlled, Parallel Group Study to Compare Perrigo's Brinzolamide Ophthalmic Suspension 1% to Azopt® in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes

Phase 3; n=495; evaluation: not stated. Reported fields: -; -; 8AM Day 14(Mean) = -3.80 mmHG (Standard Deviation, 2.719)

A BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPT® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Phase 1/2; n=637; evaluation: not stated. Reported fields: IOP(Mean) = 19.89 mmHg (Standard Deviation, 3.183); IOP(Mean) = 20.07 mmHg (Standard Deviation, 3.269); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Brinzolamide addresses Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 31 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CAs records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-04-23	Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals	Approved	Financial terms not disclosed
2026-03-24	Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109	Approved	US$100.0M stated total
2025-12-17	EssexBio Forms Strategic Cooperation with Kenvue for Motrin®, Tylenol® and Rhinocort®	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Method for preparing brinzolamide intermediate”. The milestone feed surfaced a patent-application signal described as “Brinzolamide leciplex composition for treating glaucoma”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of sterile brinzolamide”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO